drug · antibody drug conjugate
ifinatamab deruxtecan
pre_registrationupdated 5mo agoby Daiichi Sankyo Co Ltd🔗 ChEMBL
community read0 votes
Antibody drug conjugate drug with a maximum clinical stage of Phase 3 (across all indications), with 2 investigational indications.
indications
indications
NSCLCBreast CancerMelanoma
all catalysts(0)
nothing on the calendar yet
Trials studying ifinatamab deruxtecan
- phase2A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
- phase2A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- phase3A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- —Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
- phase2A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- phase3A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- phase2KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- phase2A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
News(7)
- Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitorMerck continues to diversify its cancer efforts as the clock ticks down on Keytruda’s patent, picking up rights to a preclinical oncology asset in a deal that could exceed $2 billion.biospace · 6d ago
- Merck, Daiichi end plans to seek speedy approval of lung cancer ADCThe FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.biopharma_dive · 6d ago
- Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADCMerck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab deruxtecan is a “net positive” for rivals like GSK and Roche, according to RBC Ca…biospace · 6d ago
- Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B dealDaiichi Sankyo and Merck & Co. have withdrawn an antibody-drug conjugate (ADC) filing after the FDA said they lacked the data for accelerated approval in a lung cancer population.fiercebiotech · 6d ago
- GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with MerckGSK’s risvutatug rezetecan has achieved a median overall survival of 18.5 months in a phase 3 trial, painting the antibody-drug conjugate as a threat to Amgen and Merck & Co. in the lung cancer field.fiercebiotech · 23d ago
- Daiichi’s pipeline falls behind rivals as cash flow nears peak: analystsWith Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.biospace · 2mo ago
- GSK partner Hansoh reports another phase 3 win for priority ADCHansoh Pharmaceutical has guided its GSK-partnered, B7-H3-directed antibody-drug conjugate to another phase 3 win in China.fiercebiotech · 2mo ago
Data sources
last refreshed 59m ago
Found something off?
comments(0)
5-min edit window · permanent after that